IHC Single Marker with Reporting MDM2

This test evaluates the presence and quantity of the MDM2 protein in your cells. MDM2 is essential for controlling cell division and preventing abnormal growth. Monitoring MDM2 levels can aid in diagnosing conditions where this protein plays a significant role.

• Identifying and assessing specific biomarkers.
• Determining the characteristics of certain diseases.
• Personalising treatment strategies based on molecular information.
• Guiding targeted therapies.
• Predicting disease progression and recurrence.

This test is recommended for:

• Diagnosis of cancerous growths.
• Monitoring the response to cancer treatment.
• Detecting specific markers for tailored therapies.
• Assessing tumour aggressiveness.
• Patients with suspicious lumps or masses.
• Individuals with a family history of cancer.

An abnormal range may indicate overexpression of MDM2, linked to certain cancers like sarcoma or liposarcoma. Further evaluation would be needed to confirm the diagnosis and plan appropriate treatment. Consult your doctor promptly for interpretation and next steps.

During this test:

• A sample is collected from the affected tissues.
• The laboratory will analyse the sample using special staining techniques.
• Minimal discomfort during the sampling procedure.

Before the test:

• Ensure relevant clinical and radiological details are provided.
• Attach the original Histopathology report for comprehensive analysis by experts.
• No specific dietary or lifestyle preparations are usually needed.
• Follow any specific instructions given by your healthcare provider.

The following tests can complement the IHC Single Marker with Reporting MDM2:

• Tumour Mutational Burden Testing: Evaluates genetic alterations within tumours.
• PD-L1 Expression Testing: Assesses a protein's presence to guide immunotherapy decisions.
• HER2/neu Testing: Identifies an oncogene frequently found in breast cancer cases.

Immunohistochemistry for MDM2 or MDM2 Protein Expression Test.

Liposarcoma is a type of soft tissue cancer that originates in fat cells. It commonly presents as a slow-growing mass in the limbs or abdomen. Diagnosis often involves imaging tests, biopsies, and molecular testing like the IHC Single Marker with Reporting MDM2 for accurate identification and targeted treatment planning.